Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5213224 | 0.93 | SLC6A2 (1.00) | SLC6A2SLC6A4 | |
| SCHEMBL5216022 | 0.93 | SLC6A2 (1.00) | SLC6A2SLC6A4 | |
| SCHEMBL5214231 | 0.92 | SLC6A2 (1.00) | SLC6A2SLC6A4 | |
| SCHEMBL5215131 | 0.87 | SLC6A2 (0.77) | SLC6A2SLC6A4 | |
| SCHEMBL5219270 | 0.85 | SLC6A2 (1.00) | SLC6A2SLC6A4 | |
| SCHEMBL5217381 | 0.85 | SLC6A2 (1.00) | SLC6A2SLC6A4 | |
| SCHEMBL5215335 | 0.84 | SLC6A2 (1.00) | SLC6A2SLC6A4 | |
| SCHEMBL5213378 | 0.82 | SLC6A2 (1.00) | SLC6A2SLC6A4 | |
| SCHEMBL5213642 | 0.80 | SLC6A2 (0.66) | SLC6A2SLC6A4 | |
| SCHEMBL5215847 | 0.80 | SLC6A2 (0.90) | SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1622874-B1 | 3,4-DIHYDRO-1H-QUINOLIN-2-ONE DERIVATIVES AS NOREPINEPHRINE REUPTAKE INHIBITORS | LILLY CO ELI (US) | 2007-10-03 | — | — | EP | disclosed |
| US-20070105845-A1 | Quinolone derivatives | ELI LILLY AND COMPANY PATENT DIVISION (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070105960-A1 | Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors | ELI LILLY AND COMPANY (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070032554-A1 | Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors | ELILILLY AND COMPANY A CORPORATION | 2007-02-08 | — | — | US | disclosed |
| US-20070015786-A1 | Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition | ELI LILY AND COMPANY (US) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105845-A1 | Quinolone derivatives | NQO2, NQO1, RECQL | SLC6A2 1044/4885SLC6A4 1157/4885 |
| US-20070105960-A1 | Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors | SLC6A2, SLC6A3, SLC6A4 | SLC6A2 1/4885SLC6A4 3/4885 |
| US-20070032554-A1 | Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors | SLC6A2, SLC6A4, SLC6A3 | SLC6A2 1/4885SLC6A4 2/4885 |
| US-20070015786-A1 | Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition | SLC6A2, SLC6A4, HTR5A | SLC6A2 1/4885SLC6A4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.